Annual Congress Berlin 2001

Saturday, 22.09.2001
Sunday, 23.09.2001
Monday, 24.09.2001
Tuesday, 25.09.2001
Wednesday, 26.09.2001

Citations should be made in the following way: Authors. Title. Eur Respir J 2004; 18: Suppl. 33, abstract number.

Material from 2001:

3025 Abstracts

Material from 2001: Show

Therapy for non-small cell lung cancer

Poster Discussion
Chairs: K. Zarogoulidis (Thessaloniki, Greece), A. Meert (Brussels, Belgium)

Download all media

Do thoracic surgeons outperform general surgeons in lung cancer surgery? A single centre study L. Vogt, P. J. A. van de Starre, J. G. van der Star, J. W. K. van den Berg (Zwolle, The Netherlands)
Surgery of NSCLC with ipsilateral intrapulmonary metastases A. Akopov, Y. Levashev (Saint-Petersburg, Russia)
Results of low dose iridium 192 brachytherapy in malignant airway stenosis J. Warzelhan, M. Mueller, K. Henne, H. Frommhold, J. Hasse (Freiburg, Germany)
High dose rate endobronchial brachytherapy in the palliative management of bronchial cancer - comparison of different doses J. Skowronek, T. Piorunek, S. Cofta, K. Swierkocki, W. Mlynarczyk (Poznan, Poland)
Assessment of endoscopic response subsequent to brachytherapy and external beam irradiation for non-small cell lung cancer E. Bukurov-Sudjic, N. Jovanovic (Belgrade, Yugoslavia)
Pattern of response and recurrence after induction chemotherapy and [dsquote]involved field[dsquote] thoracic radiotherapy to 70 Gy in stage III NSCLC J. A. Burgers, S. Senan, R. J. van Klaveren, S. S. Oei, J. R. van Sornsen de Koste, T. A. W. Splinter, J. P. van Meerbeeck, Rotterdam Oncologic Thoracic Studygroup (ROTS) (Rotterdam, The Netherlands)
A phase 2 study of induction carboplatin (CBDCA) and dosetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) A. Ikeda, N. Katakami, M. Okazaki, T. Hasegawa, T. Nishimura, S. Fujita, C. Nishio, B. Umeda, S. Nishiuchi, K. Hirokawa (Kobe, Japan)
Home-based monochemotherapy for lung cancer: assessment of acceptability and costs C. Chouaid, C. Furhman, K. Atassi, J. P. L'Huillier, B. Housset, I. Monnet (Creteil, France)
Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer R. Suzuki, H. Taniguchi, Y. Noda, S. Matsumoto, J. Shindoh, K. Baba, K. Suzuki, Y. Kondoh, Y. Tanigawa, T. Hiramatsu, M. Takeuchi, K. Yamaki, K. Takagi (Nagoya, Aichi, Japan)
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) G. M. Corbo, G. Gualano, K. Geraneo, S. Cardo, G. Pezzuto, L. Trodella, G. Mantini, M. Balducci, R. M. D'Angelillo, G. Iuliano, S. Valente (Rome, Italy)
*Comparison of vinorelbine containing dublet versus* triplet schedule (vinorelbine cisplatin versus vinorelbine-ifosfamide cisplatin) in NSCLC** M. Pešek, M. Tamášová, G. Čertiková, M. Lisá (Czech Republic; , Slovakia)
Effects of treatment with etoposide and cisplatinum in nonsmall cell lung cancer patients-a single institution experience M. M. Radovic, D. V. Djordjevic, D. S. Zivkovic, S. M. Golubovic, G. Pejovic (Nis, Yugoslavia)
Second-line weekly docetaxel in advanced non-small cell lung cancer M. Serke, D. Argiropulos, N. Schoenfeld, R. Loddenkemper (Berlin, Germany)
A prospective study on lung toxicity in patients treated with paclitaxel and carboplatin I. Dimopoulou, H. Galani, A. Samakovli, C. Roussos, M. A. Dimopoulos (Athens, Greece)
Value of Tc-99m-MIBI scintigraphy in predicting the cytostatic responsiveness of the non-small lung cancer V. Pechman, J. Zahlava (Plzen, Czech Republic)
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) M. Zaleska, J. Zych, A. Sakowicz, M. Szturmowicz, E. Rowinska-Zakrzewska (Warsaw, Poland)
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) R. Jankowska, E. Passowicz-Muszynska, J. Kornafel, I. Gisterek, J. Kolodziej, M. Marciniak (Wroclaw, Poland)
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients R. Pavicevic, G. Bubanovic, A. Krajna, J. MiliČic, P. Bialk, L. Pavicevic, D. S. Rokotov (Zagreb, Jastrebarsko, Croatia; , Germany)
Treatment choices in lung cancer patients with brain metastasis E. S. Budisin, V. Canak, S. Jovanovic, S. Milovic, N. I. Budisin (Sremska Kamenica, Yugoslavia)
Possibilities of palliative combined therapy for extensive nonsmall cells lung cancer M. K. Mistulova, V. A. Gerasin, S. V. Orlov, L. V. Stelmakh, T. V. Bigday (St.Petersburg, Russia)